Skip to content
Search
Please enter at least 3 characters.

Latest Stories

GSK, Sanofi delay data on Covid-19 vaccine booster candidate until 2022

GlaxoSmithKline (GSK) and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot.

The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more time to test the booster on more people who have not been infected by the virus before they can submit data to regulators.


The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said.

"To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022."

No safety concerns were identified.

This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.

They were forced to start a new clinical trial of the vaccine candidate after trials last year showed an insufficient immune response in older people.

In May, the companies had said the vaccine could be approved by the year-end after initially targeting the first half of the year.

The protein-based vaccine uses the same technology as one of Sanofi's seasonal influenza vaccines coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

At the end of September, Sanofi dropped its plans for its own mRNA-based Covid-19 vaccine because of the dominance achieved by BioNTech-Pfizer and Moderna in using the technology to fight the pandemic.

Booster shot

"The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination", the companies said in a statement.

The booster shot has been tested for all age groups and for people who have received four of the most widely approved shots -- AstraZeneca, Johnson & Johnson, Moderna and Pfizer/BioNTech - as part of their primary vaccine.

It was administered between four and ten months after a complete primary vaccination schedule. The Omicron variant was not circulating during the trial.

"Preliminary results from the VAT0002 clinical trial investigating the safety and immunogenicity of the booster showed neutralizing antibodies increased nine to 43-fold regardless of the primary vaccine received (AstraZeneca, Johnson & Johnson, Moderna, Pfizer/BioNTech) and for all age groups tested", Sanofi said.

The company said this was the most "comprehensive" booster trial to date as European countries grapple with a new wave of COVID-19 infections fuelled by the Delta variant of the virus and are gearing up for the new more contagious Omicron variant.

Sanofi also it was continuing "its contribution to global public health needs" with the manufacturing of up to half a billion doses from BioNTech/Pfizer, Moderna, and Johnson & Johnson vaccines.

More For You

Pharmacies NHS weight loss jabs

Pharmacies already sell the medication as a private service

Pic credit: iStock

Pharmacies in line to roll out NHS weight loss jabs

Pharmacies are “best placed” to deliver a planned rollout off greater access to weight loss jabs which could benefit 3.4 million people in England.

Reports today claim the government is looking at trials that would see the medication made available following a short, over-the-counter consultation for the price of an NHS prescription.

Keep ReadingShow less
Numark welcomes hub and spoke change, but calls for clear economic model

The H Human Medicines Regulations amendments will come into force on 1 October 2025.

Image credit: Getty Images

Hub and spoke dispensing between separate pharmacy businesses to begin in October

Community Pharmacy England (CPE) has confirmed that the government has laid amendments to the Human Medicines Regulations 2012 (HMR) in Parliament, marking a crucial step towards enabling hub and spoke dispensing between separate community pharmacy businesses.

The Human Medicines (Amendments Relating to Hub and Spoke Dispensing etc.) Regulations 2025 are set to come into force on 1 October 2025.

Keep ReadingShow less
Lib Dems condemn rising unsolved crimes, say shoplifting and burglary ‘effectively decriminalised’

Leicestershire police recorded the lowest charge rate for shoplifting in the country.

Gettyimages

Shoplifting and burglary ‘effectively decriminalised’, warn Lib Dems as unsolved crimes soar

The Liberal Democrats have raised alarm over what they describe as the “decriminalisation” of burglary and shoplifting, as new data reveals that the vast majority of such offences across Britain are going unsolved.

Figures revealed by the House of Commons Library research, commissioned by the party, showed that only 5.25 per cent of shoplifting offences in London last year led to a suspect being charged.

Keep ReadingShow less
RPS and HEIW extend independent prescribing learning programme for pharmacists in Wales

The programme is designed to support pharmacists delivering the Pharmacy Independent Prescribing Service in Wales.

gettyimages

Independent prescribing learning programme for pharmacists in Wales extended till 2028

The Royal Pharmaceutical Society (RPS) and Health Education and Improvement Wales (HEIW) have announced a three-year extension of their successful learning programme designed to support pharmacists delivering the Pharmacy Independent Prescribing Service (PIPS) in Wales.

Originally launched in 2024, the programme equips pharmacists with the essential knowledge, skills, and confidence needed to provide excellent patient care as independent prescribers.

Keep ReadingShow less
NPA’s first female vice-chair Sukhi Basra

NPA’s first female vice-chair Sukhi Basra

Sukhi Basra

NPA’s first female vice-chair vows to “open doors” for next generation

The National Pharmacy Association’s (NPA) new vice-chair has vowed to be an “advocate” for community pharmacy and see the sector get the recognition it deserves.

Sukhi Basra created history this week when she became the first female vice-chair of the NPA and she is determined to ensure she makes a lasting change in her new role.

Keep ReadingShow less